Table S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation
Key Points
Key points are not available for this paper at this time.
Abstract
Table S5. Preliminary mutation analysis
Demander à l'IA
Like
Bookmark
Share
Demander à l'IA
Like
Bookmark
Share
Table S5 from A Next-Generation BRAF Inhibitor Overcomes Resistance to BRAF Inhibition in Patients with BRAF-Mutant Cancers Using Pharmacokinetics-Informed Dose Escalation | Synapse